Lulizumab pegol
Lulizumab pegol (also known as BMS-931699 or MDX-1106) is a monoclonal antibody designed for the treatment of autoimmune diseases. It is developed by Bristol-Myers Squibb.
Mechanism of Action[edit]
Lulizumab pegol works by targeting and inhibiting the PD-1 receptor, a protein that plays a major role in suppressing the immune system. By blocking this receptor, the drug enhances the body's immune response against disease-causing cells.
Clinical Trials[edit]
Lulizumab pegol has undergone clinical trials for the treatment of various autoimmune diseases, including lupus and rheumatoid arthritis. However, as of 2020, it has not yet been approved by the FDA or any other regulatory authority.
Side Effects[edit]
Like all drugs, lulizumab pegol can cause side effects. The most common ones reported in clinical trials include fatigue, nausea, and headaches. Severe side effects can include pneumonia and other serious infections due to the drug's effect on the immune system.
See Also[edit]
References[edit]
<references />
 | This medical article is a stub. You can help WikiMD by expanding the page. |
| This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
